Acinetobacter infections - Pipeline Insight, 2024

Acinetobacter infections - Pipeline Insight, 2024

DelveInsight’s, “Acinetobacter infections - Pipeline Insight, 2024,” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Acinetobacter infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Acinetobacter infections Understanding

Acinetobacter infections: Overview

Acinetobacter are gram-negative aerobic bacilli or coccobacilli that belong to the family Moraxellaceae. They are ubiquitous and can survive on dry surfaces for up to a month and are commonly carried on the skin of health care workers, increasing the likelihood of patients being colonized and medical equipment being contaminated. There are many species of Acinetobacter; all can cause human disease, but Acinetobacter baumannii (AB) accounts for about 80% of infections. Acinetobacter easily colonize tracheostomy sites and can cause community-acquired bronchiolitis and tracheobronchitis in healthy children and tracheobronchitis in immunocompromised adults. Hospital-acquired Acinetobacter pneumonias are frequently multilobar and complicated. Secondary bacteremia and septic shock are associated with a poor prognosis.

""Acinetobacter infections - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Acinetobacter infections pipeline landscape is provided which includes the disease overview and Acinetobacter infections treatment guidelines. The assessment part of the report embraces, in depth Acinetobacter infections commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acinetobacter infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Acinetobacter infections R&D. The therapies under development are focused on novel approaches to treat/improve Acinetobacter infections.

Acinetobacter infections Emerging Drugs Chapters

This segment of the Acinetobacter infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Acinetobacter infections Emerging Drugs

• Sulbactam-durlobactam: Entasis Therapeutics

Durlobactam (DUR; previously designated ETX2514) is a novel, broad-spectrum and potent inhibitor of Class A, C, and D β-lactamases. Sulbactam (SUL) is a β-lactam antibiotic with activity against Acinetobacter baumannii; however, β-lactamase-mediated resistance to sulbactam is now widespread rendering it generally ineffective. In preclinical studies, durlobactam inhibits the β-lactamases commonly found in A. baumannii thus restoring sulbactam’s activity. The company is developing SUL-DUR (previously designated ETX2514SUL), a combination of β-lactam antibiotic and a β-lactamase inhibitor for the treatment of serious infections cuased by Acinetobacter, including multidrug-resistant (MDR) strains. In October 2021 the company announced positive topline results for sulbactam-durlobactam (SUL-DUR) from Phase 3 ATTACK trial. SUL-DUR met the primary endpoint of 28-day all-cause mortality in patients with carbapenem-resistant ABC infections (CRABC m-MITT* population in Part A of the study), demonstrating statistical non-inferiority versus colistin. SUL-DUR has been designated a Qualified Infectious Disease Product (QIDP) by the U.S. Food and Drug Administration and awarded Fast Track status.

Further product details are provided in the report……..

Acinetobacter infections: Therapeutic Assessment

This segment of the report provides insights about the different Acinetobacter infections drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Acinetobacter infections

There are approx. 25+ key companies which are developing the therapies for Acinetobacter infections. The companies which have their Acinetobacter infections drug candidates in the most advanced stage, i.e. phase III include, Entasis Therapeutics.

• Phases

DelveInsight’s report covers around 25+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Acinetobacter infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Acinetobacter infections: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Acinetobacter infections therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acinetobacter infections drugs.

Acinetobacter infections Report Insights

• Acinetobacter infections Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Acinetobacter infections Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Acinetobacter infections drugs?
• How many Acinetobacter infections drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Acinetobacter infections?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Acinetobacter infections therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Acinetobacter infections and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Entasis Therapeutics
• Spero Therapeutics
• Omnix Medical
• ABAC Therapeutics
• Venatorx Pharmaceuticals
• Armata Pharmaceuticals
• Technophage, SA
• Aridis Pharmaceuticals
• Forge Therapeutics
• AiCuris
• Wockhardt
• Tetraphase Pharmaceuticals
• Geom Therapeutics
• Atterx Biotherapeutics
• Hsiri Therapeutics
• Antabio
• TAXIS Pharmaceutical
• Vaxdyn
• ContraFect Corporation (CFRX)
• Debiopharm
• Idorsia
• Tetraphase
• Telum Therapeutics
• Bioharmony Therapeutics
• Destiny Pharma
• BioVersys

Key Products

• Sulbactam-durlobactam
• SPR 206
• OMN 7
• ESKAPE Pathogens bacteriophages
• TP-102
• AR-401
• LpxC inhibitors
• AIC 499
• WCK 5222
• VNRX-5113
• Eravacycline
• GT-1
• GT-055
• GN-4474
• ANT 3310
• VXD-001
• Debio1454
• TP-6076
• BH02
• XF-73
• BV100